A method for modulating splicing of Sirtuin 1 includes administering or adding to a subject 3-methyl-1-phenyl-2-pyrazolin-5-one, a physiologically acceptable salt thereof, a hydrate thereof, and/or a solvate thereof.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
2.
Triazine compound salt, crystal form thereof, and production method therefor
The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
3.
PHARMACEUTICAL COMPOSITION FOR HAILEY-HAILEY DISEASE AND USE THEREOF
A pharmaceutical composition for Hailey-Hailey disease contains 5-methyl-2-(1-piperazinyl)benzenesulfonic acid. The compound may be in a form of an anhydrate thereof, a salt thereof, a hydrate or solvate thereof, or a hydrate or solvate of a salt thereof, as an active ingredient. The hydrate is, for example, 5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; antiallergic medicines; antihypertensives; hypoglycemic agents; antidiabetic preparations; pharmaceutical preparations for the prevention of diabetic nephropathy; pharmaceutical preparations, namely, antiphlogistic agents; vaccine; pharmaceutical preparations for the treatment of autoimmune disease; pharmaceutical preparations for the treatment of cerebral infarction; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of erectile dysfunction
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological , psychiatric and immune system related diseases and disorders; antiallergic medicines; antihypertensives; hypoglycemic agents; antidiabetic preparations; pharmaceutical preparations for the prevention of diabetic nephropathy; pharmaceutical preparations, namely, antiphlogistic agents; vaccine; pharmaceutical preparations for the treatment of autoimmune disease; pharmaceutical preparations for the treatment of cerebral infarction; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of erectile dysfunction.
The present invention relates to a polymer which comprises constituent units (1), (2), and (3) represented by formulae (1A) to (3) (wherein each symbol is as defined in the present description), wherein the constituent units are bonded to each other. The present invention also relates to a catalyst for flow synthesis, which contains the polymer.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
A pharmaceutical composition for keratosis contains 5-methyl-2-(1-piperazinyl)benzenesulfonic acid. The compound may be in a form of an anhydrate thereof, a salt thereof, a hydrate or solvate thereof, or a hydrate or solvate of a salt thereof, and the hydrate is, for example, 5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate. The keratosis is, for example, Darier's disease or psoriasis.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosilate, and the like.
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
treatment of erythropoietic protoporphyria and X-linked
protoporphyria. Providing medical information of erythropoietic
protoporphyria and X-linked protoporphyria; providing
medical information, consultancy and advisory services.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for treatment of erythropoietic protoporphyria and X-linked protoporphyria Providing medical information about erythropoietic protoporphyria and X-linked protoporphyria; providing medical information, consultancy and advisory services
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of neurological diseases and disorders
A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject includes, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to inhibit 50% or more of CYP 11β2 beta hydroxylase's activity for 40-60% of a 24-hour period to thereby treat hypertension in the hypertensive subject.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations; pharmaceuticals; medicines for
human purposes; targeted protein degrader. Custom manufacture of pharmaceuticals. Testing, inspection or research of pharmaceuticals;
consulting services in the field of testing, inspection or
research of pharmaceuticals; providing medical and
scientific testing, inspection or research information in
the field of pharmaceuticals; conducting clinical trials for
pharmaceuticals; research and development services in the
field of pharmaceutical preparations.
C07D 253/02 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group not condensed with other rings
C07D 253/065 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations, namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; pharmaceuticals namely targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; medicines for human purposes namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; target protein degrader namely, pharmaceutical preparations for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases Custom manufacture of pharmaceuticals namely targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases Testing, inspection or research of pharmaceuticals namely targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; consulting services in the field of testing, inspection or research of pharmaceuticals namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; providing scientific information about medical testing of pharmaceuticals, and providing medical and scientific testing, inspection and research information in the field of pharmaceuticals namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; Medical and scientific research, namely, conducting clinical trials for pharmaceuticals in the field of targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases; research and development services in the field of pharmaceutical preparations namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic, immunologic, inflammatory diseases
The present invention provides a crystal of 1-{2-[(3S, 4R)-1-[(3R, 4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl) pyrrolidine-3-carbonyl]-4-(methoxymethyl) pyrrolidin-3-yl]-5-(trifluoromethyl) p henyl} piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S, 4R)-1-[(3R, 4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl) pyrrolidine-3-carbonyl]-4-(methoxymethyl) pyrrolidin-3-yl]-5-(trifluoromethyl) phenyl} piperidine-4-carboxylic acid and phosphoric acid.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula:
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula:
Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula:
and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
09 - Scientific and electric apparatus and instruments
38 - Telecommunications services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software for detecting symptoms of ALS; Downloadable software for measuring progress of ALS; Downloadable medical software for tracking change of fine motor skills; Downloadable medical software for diagnosing ALS; Downloadable medical software for testing fine motor skills; Downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Software as a Medical Device (SaMD), downloadable, for detecting symptoms of ALS; Software as a Medical Device (SaMD), downloadable, for measuring progress of ALS; Software as a Medical Device (SaMD), downloadable, for tracking change of fine motor skills; Software as a Medical Device (SaMD), downloadable, for diagnosing ALS; Software as a Medical Device (SaMD), downloadable, for testing fine motor skills; Software as a Medical Device (SaMD), downloadable, for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians Rental of smartphones; Rental of smartphones featuring embedded software for detecting symptoms of ALS, sold as a unit; Rental of smartphones featuring embedded software for measuring progress of ALS, sold as a unit; Rental of smartphones featuring embedded software for tracking change of fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for diagnosing ALS, sold as a unit; Rental of smartphones featuring embedded software for testing fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians, sold as a unit; Rental of mobile phones Software as a service (SaaS) services featuring non-downloadable software for detecting symptoms of ALS; Software as a service (SaaS) services featuring non-downloadable software for measuring progress of ALS; Software as a service (SaaS) services featuring non-downloadable medical software for tracking change of fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for diagnosing ALS; Software as a service (SaaS) services featuring non-downloadable medical software for testing fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Providing on-line non-downloadable software for medical purposes for detecting symptoms of ALS; Providing on-line non-downloadable software for medical purposes for measuring progress of ALS; Providing on-line non-downloadable medical software for tracking change of fine motor skills; Providing on-line non-downloadable medical software for diagnosing ALS; Providing on-line non-downloadable medical software for testing fine motor skills; Providing on-line non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Rental of computer hardware and computer peripherals; Rental of tablet computers
09 - Scientific and electric apparatus and instruments
38 - Telecommunications services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software for detecting symptoms of ALS; Downloadable software for measuring progress of ALS; Downloadable medical software for tracking change of fine motor skills; Downloadable medical software for diagnosing ALS; Downloadable medical software for testing fine motor skills; Downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Software as a Medical Device (SaMD), downloadable, for detecting symptoms of ALS; Software as a Medical Device (SaMD), downloadable, for measuring progress of ALS; Software as a Medical Device (SaMD), downloadable, for tracking change of fine motor skills; Software as a Medical Device (SaMD), downloadable, for diagnosing ALS; Software as a Medical Device (SaMD), downloadable, for testing fine motor skills; Software as a Medical Device (SaMD), downloadable, for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians Rental of smartphones; Rental of smartphones featuring embedded software for detecting symptoms of ALS, sold as a unit; Rental of smartphones featuring embedded software for measuring progress of ALS, sold as a unit; Rental of smartphones featuring embedded software for tracking change of fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for diagnosing ALS, sold as a unit; Rental of smartphones featuring embedded software for testing fine motor skills, sold as a unit; Rental of smartphones featuring embedded software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians, sold as a unit; Rental of mobile phones Software as a service (SaaS) services featuring non-downloadable software for detecting symptoms of ALS; Software as a service (SaaS) services featuring non-downloadable software for measuring progress of ALS; Software as a service (SaaS) services featuring non-downloadable medical software for tracking change of fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for diagnosing ALS; Software as a service (SaaS) services featuring non-downloadable medical software for testing fine motor skills; Software as a service (SaaS) services featuring non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Providing on-line non-downloadable software for medical purposes for detecting symptoms of ALS; Providing on-line non-downloadable software for medical purposes for measuring progress of ALS; Providing on-line non-downloadable medical software for tracking change of fine motor skills; Providing on-line non-downloadable medical software for diagnosing ALS; Providing on-line non-downloadable medical software for testing fine motor skills; Providing on-line non-downloadable medical software for collecting test data of fine motor skills of patients with ALS and providing the data to clinicians; Rental of computer hardware and computer peripherals; Rental of tablet computers
28.
Triazine compound salt, crystal form thereof, and production method therefor
The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A neuromuscular disease evaluation device that is less invasive, highly sensitive, quantitative and objective, and capable of easily evaluating neuromuscular diseases. A device for evaluating motor functions related to neuromuscular diseases, comprising: a memory unit storing a reference value for evaluating a predetermined movement, which is calculated based on a position of at least one body part; an analysis unit for identifying a position of a body part of the user by analyzing information based on an image captured of the predetermined movement, including the user's body; and an evaluation unit for evaluating the motor function based on the numerical value calculated based on the position of the body part of the user and the reference value.
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
A myoregulin inhibitor such as an antisense oligonucleotide against myoregulin or an anti-myoregulin antibody is used as an active ingredient of a prophylactic or therapeutic agent for a muscle disease such as muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disused muscular atrophy, and sarcopenia.
A medicament for treatment or prevention of porphyria, comprising 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof as an active ingredient, wherein the dose of the 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or the pharmaceutically acceptable salt or cocrystal thereof is 50 to 500 mg/day.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A pharmaceutical composition of 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a salt thereof is provided. The composition is superior in storage stability and can suppress production of related substances.
A pharmaceutical composition of 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a salt thereof is provided. The composition is superior in storage stability and can suppress production of related substances.
An excipient selected from dibasic calcium phosphate, calcium dihydrogen phosphate, dibasic sodium phosphate, and sodium dihydrogen phosphate is used.
2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing medical information about Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP); providing medical information, consultancy and advisory services; medical assistance services; providing an internet web site for medical professionals and medical patients featuring information relating to Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP); dietary and nutritional guidance; health care services, namely providing treatment for Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP); health counselling
The present invention provides a crystal of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of central nervous system diseases, namely amyotrophic lateral sclerosis (ALS); Free radical scavenger for pharmaceutical purposes; Neuroprotective agents, namely pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)
The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof. Specifically, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of derivatizing a compound represented by formula II or a salt thereof into a corresponding compound represented by formula III, a salt thereof, or a derivative thereof, then a step of reacting the resulting compound, a salt thereof, or a derivative thereof with aminourea or a salt thereof in water to produce a compound represented by formula IV or a salt thereof, and then a step of reacting the resulting compound or a salt thereof in the presence of a base.
(wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group)
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin
metabolism disorders; pharmaceutical preparations for
treatment of porphyria; pharmaceutical preparations for
treatment of photodermatoses; pharmaceutical preparations
for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; medicines for human purposes;
pharmaceutical preparations for the treatment of central
nervous system diseases; pharmaceutical preparations for the
treatment of amyotrophic lateral sclerosis (ALS); free
radical scavenger for pharmaceutical purposes;
pharmaceutical preparations for protection against free
radicals; neuroprotective agents; pharmaceutical
preparations for the treatment of acute ischaemic stroke.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin
metabolism disorders; pharmaceutical preparations for
treatment of porphyria; pharmaceutical preparations for
treatment of photodermatoses; pharmaceutical preparations
for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin
metabolism disorders; pharmaceutical preparations for
treatment of porphyria; pharmaceutical preparations for
treatment of photodermatoses; pharmaceutical preparations
for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin
metabolism disorders; pharmaceutical preparations for
treatment of porphyria; pharmaceutical preparations for
treatment of photodermatoses; pharmaceutical preparations
for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin
metabolism disorders; pharmaceutical preparations for
treatment of porphyria; pharmaceutical preparations for
treatment of photodermatoses; pharmaceutical preparations
for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin
metabolism disorders; pharmaceutical preparations for
treatment of porphyria; pharmaceutical preparations for
treatment of photodermatoses; pharmaceutical preparations
for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; medicines for human purposes;
pharmaceutical preparations for the treatment of
neurological diseases and disorders; pharmaceutical
preparations for the treatment of psychiatric diseases and
disorders; pharmaceutical preparations for the treatment of
tardive dyskinesia; pharmaceutical preparations for the
treatment of Tourette syndrome; pharmaceutical preparations
for the treatment of dystonia; pharmaceutical preparations
for the treatment of movement disorders; pharmaceutical
preparations for the treatment of tics.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of central nervous system diseases, namely amyotrophic lateral sclerosis (ALS); Free radical scavenger for pharmaceutical purposes; Neuroprotective agents, namely pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of central nervous system diseases, namely amyotrophic lateral sclerosis (ALS); Free radical scavenger for pharmaceutical purposes; Neuroprotective agents, namely pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of central nervous system diseases; Pharmaceutical preparations for protection against free radicals; Pharmaceutical preparations for removing free radicals from the human bodies; Neuroprotective medicines; Pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of central nervous system diseases, namely amyotrophic lateral sclerosis (ALS); Free radical scavenger for pharmaceutical purposes; Neuroprotective agents, namely pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)
Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like.
A compound represented by the formula (I) or a pharmacologically acceptable salt thereof.
wherein each symbol is as defined in the DESCRIPTION.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
